NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the remedy of palmar hyperhidrosis making use of its patented microchannel technologies™. DTX-024 is a very purified and clinically tested injectable neuromodulator derived from neurotoxins developed by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar system for its botulinum toxin, this will be the very first in the planet, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and connected intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the speedy-developing multi-billion-dollar botulinum toxin market place.
To properly execute the technique, Aquavit has not too long ago bolstered its executive group with seasoned veterans from the market and the academia.
Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has get- and sell-side experience in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical organizations, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical organizations additional than 30 years ago, most notably at Allergan, an Abbvie Corporation, exactly where he lead deal execution for each technologies, solution, and corporation acquisitions and divestitures across a broad variety of therapeutic regions and organization units like injectable and topical healthcare aesthetics, dermatology, neurology, and ophthalmology. He serves on many boards like each public and private organizations and has been awarded many recognitions like San Diego’s 500 Most Influential folks for the previous 4 years (2019 -2022), 2020 Major Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of encounter and expertise to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and presently holds an academic position at Columbia Healthcare College.
With Aquavit’s confirmed track record of establishing and launching worldwide brands, such as AQUAGOLD®, the corporation has demonstrated their potential to effectively bring revolutionary items to market place. With their deep expertise of botulinum toxin and in depth network of physicians, Aquavit is properly-positioned to make a considerable effect in the market.
“The neurotoxin market place is expanding swiftly, with rising demand for revolutionary items and customized remedy plans. There is presently no FDA approval for palmar hyperhidrosis and by way of our novel route of administration we will be capable to present new options to meet the evolving desires of individuals in pathologies that are incredibly debilitating. The provision of access for this population is a step in the suitable path towards enhancing their wellness and properly-becoming. ” Churl-Su Kwon, CMO Aquavit.
Aquavit is an revolutionary healthcare corporation that gives a extensive variety of proprietary pharmaceutical, biotech and healthcare device technologies. Aquavit focuses on customized medicine to enhance patients’ wellness, maximize the efficiency of our healthcare neighborhood, and assistance the pharmacoeconomics of payers.
View original content material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-extra-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings